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Although prolonged genetic pressure has been conjectured to be necessary for the even-
tual development of tumor immune evasion mechanisms, recent work is demonstrating
that early genetic mutations are capable of moonlighting as both intrinsic and extrinsic
modulators of the tumor immune microenvironment. The indoleamine 2,3-dioxygenase-
1 (IDO) immunoregulatory enzyme is emerging as a key player in tumor-mediated
immune tolerance. While loss of the tumor suppressor, BIN-1, and the over-expression
of cyclooxygenase-2 have been implicated in intrinsic regulation of IDO, recent findings
have demonstrated the loss ofTβRIII and the upregulation of Wnt5a by developing cancers
to play a role in the extrinsic control of IDO activity by local dendritic cell populations residing
within tumor and tumor-draining lymph node tissues. Together, these genetic changes are
capable of modulating paracrine signaling pathways in the early stages of carcinogenesis to
establish a site of immune privilege by promoting the differentiation and activation of local
regulatoryT cells. Additional investigation of these immune evasion pathways promises to
provide opportunities for the development of novel strategies to synergistically enhance
the efficacy of the evolving class of T cell-targeted “checkpoint” inhibitors.
Keywords: indoleamine 2,3-dioxygenase, dendritic cells, tumor immune evasion, β-catenin, tumor immunotherapy,
Wnt5a, type IIITGF-β receptor, COX-2
INTRODUCTION
Indoleamine 2,3-dioxygenase-1 (IDO) is a heme-containing
enzyme known to catalyze the rate limiting step in the degra-
dation of the essential amino acid tryptophan to its metabolic
byproducts known collectively as the kynurenines (1). Although
initially felt to play primarily an anti-microbial role, pioneering
work eventually showed this biochemical pathway to impact the
immune system by inhibiting T cell proliferation and driving the
differentiation and activation of regulatory T cells (Tregs) (2–
6). While IDO has been broadly implicated in the progression
of several cancers by aiding tumors to evade the host immune sys-
tem, the mechanisms utilized by cancers to regulate IDO activity
have remained poorly characterized (7, 8). Recent work in pre-
clinical models has revealed novel mechanisms utilized by cancers
to manipulate IDO activity within the tumor microenvironment.
Interestingly, these mechanisms have been found to be regulated
by previously defined tumor suppressors and oncogenes, which
undergo genetic alteration relatively early during tumorigenesis. In
contrast to the cancer immunoediting hypothesis, which proposes
that immune-mediated selective pressure by the adaptive immune
system is necessary before active immune tolerization mecha-
nisms develop (9), this observation suggests that subversion of
the immune system is necessary at relatively early stages of tumor
development and, in fact, occur concurrently with the process of
malignant transformation (Figure 1). This review discusses our
understanding of IDO regulation, highlights mechanisms utilized
by cancers to control IDO activity in the tumor immune microen-
vironment, and outlines pharmacological strategies for reversing
these processes to ultimately augment our immunotherapeutic
strategies for managing cancer patients.
REGULATION OF IDO EXPRESSION AND ENZYMATIC
ACTIVITY
Several factors have been shown to regulate the expression of
IDO in a cell type-specific manner in monocytes, macrophages,
endothelial cells, fibroblasts, some tumor cells, and various pop-
ulations of dendritic cells (DCs). Initial studies focused on the
process of inflammation, showing interferon-γ (IFN-γ) to be a
potent inducer of IDO expression in many cell types and demon-
strating this pathway of IDO induction to provide protection
from intracellular pathogens by depleting local tryptophan lev-
els (10, 11). Other inflammatory factors that have been shown
to regulate IDO expression include IL-1, tumor necrosis factor-
α (TNF-α), and lipopolysaccharide (LPS) (12, 13). Interestingly,
prostaglandin E2 has been observed to induce the transcription of
IDO in human monocyte-derived DCs; however, additional acti-
vation with TNF-α or LPS was noted to be necessary to achieve
full enzymatic activity (14). This is consistent with observations by
other investigators who have found that two-signals are often nec-
essary to induce maximal IDO expression by specific DC subsets
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FIGURE 1 | Early steps in carcinogenesis include immune evasion by
upregulating IDO expression in the tumor microenvironment. This model
proposes the development of immune evasion mechanisms early during
transformation, which stimulate local IDO activity prior to the development of
adaptive anti-tumor immunity and generation of the selective pressure
responsible for cancer immunoediting.
(5). Additional T cell-derived signals have also been demonstrated
to play a role in regulating IDO expression including reverse signal-
ing via B7 co-stimulatory molecule (CD80/CD86) cross-linking
on the surface of antigen-presenting cells (APCs) (15–18). Using
this mechanism, Tregs constitutively expressing CTLA-4 condi-
tion DCs by stimulating IDO expression and, in turn, suppressing
local T cell proliferation, thereby establishing a state of immune
tolerance. Later work revealed this B7 reverse signaling mecha-
nism to be dependent upon the activation of the non-canonical
NFκB signaling pathway, a mechanism also responsible for the
induction of IDO following stimulation by other cell surface recep-
tors including CD40 and the glucocorticoid-induced TNF receptor
(GITR) (19).
It has been generally proposed that IDO activation signals have
evolved to provide a negative feedback mechanism to dampen local
inflammatory processes and prevent immune-mediated pathol-
ogy. However, more recent studies have shown the immunosup-
pressive cytokine, TGF-β, to induce novel IDO functionality by
specific subtypes of DCs including the murine CD8+ splenic DC
subset as well as the plasmacytoid DC (pDC) population (20, 21).
These studies revealed TGF-β to stimulate the expression and Fyn-
dependent phosphorylation of IDO, enabling this protein to also
serve as a scaffolding molecule for downstream signaling ulti-
mately leading to the expression of both TGF-β and IDO itself.
As opposed to the rapid and short-lived induction of IDO expres-
sion by IFN-γ, the stimulation of IDO expression by TGF-β is
thought to be durable and to serve as a mechanism for generating
long-term immune tolerance. This post-translational modifica-
tion of IDO by TGF-β also has additional implications in terms
of its regulation. In inflammatory conditions, exposure to IL-6
promotes the degradation of IDO by upregulating suppressor of
cytokine signaling 3 (SOCS3), which binds to a phosphorylated
immunoreceptor tyrosine-based inhibitory motif (ITIM) in IDO
and promotes its proteosomal degradation (22).
Additional post-translational regulatory mechanisms have
been elucidated, which are also capable of contributing to the
regulation of IDO activity. This includes the nitration of various
IDO tyrosine residues by peroxynitrite, a byproduct of nitric oxide
(NO) and superoxide, which has also been shown to dampen IDO
enzyme activity in macrophages (23). This is consistent with other
findings showing NO to directly inhibit IDO activity by binding
to its active site heme moiety (24). Indeed, previous work indi-
cates that the reduction–oxidation status of the cell is capable of
modulating activity of the IDO holoenzyme by interfering with
the heme biosynthetic pathway (25).
It is clear that there are multiple mechanisms, which may
regulate IDO on both the transcriptional and post-translational
levels. However, the biological contexts in which these regulatory
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mechanisms affect IDO activity remain unclear. This is partic-
ularly true for the process of carcinogenesis, which occurs in a
biochemically altered environment. Several studies have supported
an important role for IDO in the generation of an immunotoler-
ant tumor microenvironment that facilitates tumor progression
(26–28). These findings indicate that the mechanisms utilized by
cancers to modulate IDO expression and activity may be central
to understanding the highly complex process of carcinogene-
sis. Here, we discuss recent studies investigating the mechanisms
that cancers utilize to manipulate local IDO activity within the
immune microenvironment in order to facilitate their metastatic
progression.
TUMOR-MEDIATED REGULATION OF INTRINSIC IDO1
EXPRESSION
The expression of IDO by many cancer types has been correlated
with inferior progression-free and overall survival (29). However,
the regulation of IDO expression by malignant tissues has been
poorly understood. In 2005, the first mechanism by which sev-
eral solid tumors can regulate the intrinsic expression of IDO
was described. This work focused on the BAR adapter-encoding
gene BIN-1, a tumor suppressor previously found to be down-
regulated in several transformed cell lines and demonstrated to
suppress the transformational activity of MYC by interacting with
its N-terminus (30). Subsequent studies revealed BIN-1 to inter-
fere with malignant transformation utilizing several mechanisms
beyond the suppression of MYC activity and additional work
showed BIN-1 to play the role of a tumor suppressor in several
cancer types including melanoma, breast cancer, colon cancer,
and prostate cancer (31–33). After noting that BIN-1 seemed
to suppress the development of a transformed epithelial tumor
model via an immune-dependent mechanism, Muller and col-
leagues noted that the deletion of Bin-1 significantly enhanced
the IFN-γ-mediated upregulation of IDO expression by tumor
cells (34). Indeed, the observed enhancement in tumor growth
following Bin-1 deletion was reversed in the presence of the 1-
methyltryptophan (1-MT) IDO inhibitor only in the setting of an
intact immune system. These authors concluded that BIN-1 was
capable of modulating IDO expression by regulating the STAT1
and NFκB signaling pathways that have been previously impli-
cated in promoting the transcription of Indo, the IDO encoding
gene (Figure 2A). This represented the initial study linking IDO
regulation to an intrinsic tumor suppressor pathway by showing
that the loss of Bin1 tumor expression contributes to tumorigenesis
by driving cellular proliferation while simultaneously concealing
itself from detection and destruction by the host immune system.
This work prompted us to conjecture that early phases of tumor
initiation and growth will often require the evolution of multifunc-
tional genes, which regulate both cell division and/or survival, as
well as elements of the local immune microenvironment.
Cyclooxygenase-2 (COX2), another modulator of IDO expres-
sion and activity, has also been implicated in the process of
tumorigenesis and may be consistent with this hypothesis (35).
COX2 represents the inducible isoform of the cyclooxygenases
and plays a critical role in eicosanoid biosynthesis, including the
prostaglandins and leukotrienes. The initial data linking COX2
biology with carcinogenesis was provided by genetic studies
showing that when APC∆716 mice, which model the colon can-
cer syndrome, familial adenomatous polyposis, are crossed with
mice carrying an inactivating mutation in the Pgst2 gene encod-
ing COX2, offspring develop exhibiting a diminished number of
intestinal polyps (36). Since this study, several pre-malignant and
malignant tissues have been shown to express COX2 at relatively
early time points of tumorigenesis and several pro-tumorigenic
functions have been ascribed to COX2 including the promotion of
tumor-mediated angiogenesis, anti-apoptosis, and the generation
FIGURE 2 | Intrinsic and extrinsic mechanisms of IDO regulation
in the tumor microenvironment. (A) Downregulation of Bin1
expression leads to enhanced expression of IDO by tumor cells.
(B) Upregulation of cyclooxygenase-2 (COX-2) expression by tumor
cells stimulates intrinsic tumor expression of IDO. (C) Loss ofT βRIII,
the gene encoding the type IIII TGF-β receptor (TβRIII), allows for
increased TGF-β paracrine signaling in the tumor microenvironment
and the upregulation of IDO by local plasmacytoid DCs (pDCs).
(D) Increased soluble Wnt5a secretion upregulates IDO expression by
local myeloid DCs (mDCs).
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of the epidermal growth factor receptor ligand, amphiregulin (37).
One of the downstream products of COX2 activity, prostaglandin
E2 (PGE2), has been previously demonstrated to interfere with T
cell and DC function (38). Additional studies have shown COX2
and IDO expression to correlate in both human breast cancer cell
lines and human breast cancer primary tissues while other investi-
gators have found PGE2 to directly stimulate IDO expression (14,
39). Interestingly, COX2 inhibitors enhance the anti-tumor effects
of DC-based vaccines and promote tumor-specific T cell responses
in the MMTV-neu autochthonous murine mammary carcinoma
model further suggesting an immunologic role for COX2 in cancer
(35). Further studies have also shown COX2 inhibitors to aug-
ment a MUC1-based vaccine in a transgenic pancreatic cancer
model in a manner that depended on suppressed IDO activity
within tumor tissues (40). Similar roles for COX2 in promot-
ing Tregs in non-small cell lung cancer and in elevating IDO
expression in acute myeloid leukemia have also been described
(41, 42). Together, these studies suggest that COX2 represents
an important regulator of IDO function within malignant tissues
(Figure 2B). While these studies focused on investigating the rela-
tionship between COX2 expression and the intrinsic regulation of
IDO expression by tumor cells, a more recent study has shown
a COX2-expressing MCF-7 breast cancer cell line to induce IDO
expression by co-cultured fibroblasts, suggesting that paracrine
IDO regulatory networks may also be relevant during the process
of carcinogenesis (43).
CHARACTERIZING TUMOR-MEDIATED REGULATION OF
EXTRINSIC IDO1 EXPRESSION
Although it is unclear if the cell type expressing the IDO enzyme
may affect its ultimate immunologic impact in the setting of can-
cer, previous investigators have shown a relationship between local
DC expression of IDO and poor clinical prognosis in patients with
melanoma (28, 44). In light of these data, we reasoned that tumor-
derived soluble factors may have evolved to manipulate local DC
expression of this critical immune regulatory mechanism. Further,
in light of the dual role of the BIN-1 tumor suppressor described
above, we searched for soluble factors already described to have a
pro-tumorigenic role in the literature. These criteria led us to the
type III TGF-β receptor (TβRIII) that functions as a co-receptor for
the TGF-β signaling pathway by binding and presenting all three
TGF-β isoforms to the type I and II TGF-β receptor signaling com-
plex (45). TβRIII has been independently implicated in suppress-
ing cellular migration in several experimental systems through
a β-arrestin2-mediated mechanism (46, 47). Consistent with the
criteria discussed above, earlier studies also revealed TβRIII to be
shed at the cell surface and for its soluble form, sTβRIII, to bind
and suppress downstream TGF-β-mediated signaling, effectively
functioning as a molecular sink for the TGF-β cytokine (48, 49).
Additional work has demonstrated human breast cancers to down-
regulate TβRIII expression by loss of heterozygosity and for TβRIII
to impede metastatic progression of the 4T1 murine breast cancer
model (50). This loss of TβRIII expression has since been shown to
occur during the progression of several additional cancers includ-
ing pancreatic, lung, and prostate cancers (51–53). Notably, the
downregulation of TβRIII has also been demonstrated to occur at
a relatively early stage of tumorigenesis, exemplified by the loss of
TβRIII in tissue specimens histologically characterized as ductal
carcinoma in situ, an early precursor to invasive ductal carcinoma
of the breast. Additional studies showing the loss of TβRIII to
promote the epithelial-to-mesenchymal transition (EMT) in pan-
creatic cancer further suggests that this genetic alteration occurs
at a relatively early time point during carcinogenesis (53).
TGF-β has been described as a pleiotropic regulator of the
immune system capable of modulating both IDO activity and
several additional immunosuppressive pathways (54). By inhibit-
ing both T cell and NK cell proliferation and activation, as well
as promoting the differentiation of Treg populations, the TGF-
β cytokine plays an important role in maintaining peripheral
immune tolerance. We, therefore, hypothesized that the loss of
TβRIII expression by developing malignancies would allow for
enhanced TGF-β-dependent signaling in the tumor microenviron-
ment, thereby inhibiting local immune surveillance mechanisms
and ultimately promoting tumorigenesis (55). Using the 4T1
murine breast cancer model, we initially determined that TβRIII
expression suppressed metastatic progression only in immuno-
competent hosts. Consistent with this observation, further work
revealed the loss of TβRIII to be associated with the develop-
ment of an immunotolerant microenvironment characterized by
a decrease in the number of CD8+ T cells and a correspond-
ing increase in the CD4+FoxP3+ Treg population in both breast
cancer and melanoma model systems.
These findings led to the identification of an association
between TβRIII expression and suppressed levels of IDO in both
the tumor bed and within the tumor-draining lymph nodes
(TDLNs). We determined that the loss of TβRIII expression cor-
related with the upregulation of IDO by pDC populations within
TDLN tissues, the same cell population that was previously noted
to be important for the expression of IDO within TDLN tissues
(Figure 2C) (21, 27). These results also corresponded with dimin-
ished pDC and whole TDLN tissue IDO enzyme activity when
recovered from mice bearing TβRIII-expressing tumors. Since
sTβRIII is an effective inhibitor of downstream TGF-β signaling,
we hypothesized that TGF-β was a major mediator of pDC IDO
activity in the tumor microenvironment and confirmed the find-
ings of Pallotta and colleagues by showing TGF-β treatment of
purified pDCs to enhance IDO expression and enzymatic activity
(21). We then demonstrated this paracrine signaling mechanism to
be functionally relevant by demonstrating purified pDCs derived
from mice harboring TβRIII-downregulated tumors, to suppress
in vitro T cell proliferation in an IDO-dependent manner. Further,
using a doxycycline-inducible system, we showed that the earlier
the alteration in TβRIII expression by a developing tumor, the
more profound the effect on the local tumor microenvironment.
These results suggest that modulation of the immune microen-
vironment at earlier stages of tumorigenesis is associated with a
greater impact on tumor progression.
The work described above illustrates the potential for genetic
alterations within the tumor to impact local DC function and
to subvert immunosurveillance. Given the critical role that these
APCs play in orchestrating the anti-tumor immune response, it
follows that the evolution of various mechanisms to convert local
DCs into a tolerogenic state would be quite advantageous for a
developing tumor. The pathways for driving DC tolerogenesis in
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the setting of cancer remain poorly characterized; however, the
β-catenin signaling pathway has emerged as a potentially impor-
tant component of this process. This is supported by data showing
that activation of the β-catenin pathway in myeloid DCs (mDCs)
conditioned these APCs to promote the generation of IL-10-
expressing CD4+ T cells capable of suppressing the autoimmune
phenotype of a mouse model of multiple sclerosis (56). These
findings were further substantiated by in vivo experiments using
the CD11c-cre× β-catlox/lox transgenic model demonstrating the
DC-specific β-catenin pathway as an important regulator of Treg
differentiation in gastrointestinal tissues (57). These studies raised
the possibility that tumors may promote DC tolerization in the
tumor microenvironment via the expression of soluble Wnt lig-
ands. Interestingly, several members of the Wnt ligand family have
been noted to play a role in carcinogenesis. Indeed, mechanistic
studies have revealed Wnt5a to promote melanoma cell migra-
tion and invasion, ultimately leading to disease metastases (58). In
addition, increased Wnt5a expression levels in melanoma tissues
as well as diminished levels of the soluble Wnt antagonist, Dkk-1,
have been associated with an inferior clinical outcome in patients
with advanced melanoma (59–63).
Together, the above reports led us to screen the conditioned
media of several human melanoma cell lines for their ability
to stimulate downstream β-catenin signaling activity. This work
consistently showed that melanoma-derived conditioned media
was capable of inducing this signaling pathway in both reporter
cell lines and primary DCs in vitro (64). Further work using
the Tyr:CreER;BrafCA;Ptenlox/lox inducible transgenic melanoma
model, showed that TDLN DCs and tumor-infiltrating DCs asso-
ciated with developing melanomas expressed elevated levels of
known β-catenin target genes including Axin2, Ccnd1, C-myc,
and Tcf-7 relative to DCs derived from more distant lymph
node tissues. This local paracrine β-catenin signaling effect was
then confirmed in situ within the melanoma stroma and within
TDLN tissues by confocal microscopy using the Tg(TCF/Lef1-
HIST1H2BB/EGFP)61Hadj/J transgenic reporter strain, which
encodes an EGFP reporter downstream of a β-catenin-responsive
promoter containing tandem TCF/LEF1 transcription factor bind-
ing elements (65).
After verifying that this signaling pathway could be induced
within mDCs in an autochthonous model of melanoma, we
demonstrated that β-catenin was promoting tolerogenic DC
development by regulating the downstream expression of IDO.
Although recent studies had shown Wnt-mediated signaling
to stimulate expression of the immunosuppressive factor IL-10
by DCs, the effects on IDO expression were unknown (61).
Using a variety of methods including pharmacological inhibitors,
promoter–reporter systems, immunofluorescence microscopy,
and chromatin immunoprecipitation, we were able to demon-
strate that Wnt ligands robustly induced the durable upregulation
of both IDO expression and enzymatic activity by bone marrow-
derived DCs in a β-catenin-dependent manner. By performing
blocking experiments, we further noted that the soluble Wnt5a
ligand was the dominant factor in melanoma-conditioned media
in the induction of IDO by DCs and that Wnt5a was capable
of promoting IDO expression in an IFN-γ-independent man-
ner (Figure 2D). Importantly, as opposed to several other stimuli
including Wnt3a, additional work revealed Wnt5a conditioned
DCs to significantly promote the differentiation and expansion
of naïve CD4+ T cells into Tregs in an IDO-dependent manner.
Indeed, further in silico gene expression analysis has revealed a
significant association between Wnt5a and Foxp3 gene expres-
sion levels in human melanomas. Similar to BIN-1, COX2, and
TβRIII above, this work implicates Wnt5a as a factor with dual
roles in carcinogenesis including tumor invasion and metastasis,
as well as the suppression of local immune surveillance. Simi-
lar to TβRIII, Wnt5a has also been implicated in the promotion
of EMT in both pancreatic cancer and gastric cancer (66, 67).
This finding implies that Wnt5a is upregulated and is capable of
modulating the immune microenvironment at an early time point
during the process of carcinogenesis suggesting that Wnt5a likely
has an impact on the establishment of immune privilege during
the earliest stages of transformation.
THERAPEUTIC IMPLICATIONS OF IDO REGULATORY
PATHWAYS IN CANCER-MEDIATED IMMUNE EVASION
Although recent advances in immunotherapy have made sub-
stantial strides in improving clinical responses in patients with
advanced cancers, a significant fraction of these patients continue
to fail therapy. In light of the diverse array of immune evasion
mechanisms that individual cancers are able to employ to escape
detection and destruction by the host immune system, it seems
that combinatorial therapies, which target different aspects of
immune suppression will be necessary to fully realize the promise
of immunotherapy. While the majority of immunotherapy devel-
opment has targeted T cell-expressed negative regulators such
as CTLA-4 and PD-1 (68, 69), few agents are currently under
investigation, which are capable of modulating tolerogenic DCs
in the tumor microenvironment. An exception to this includes the
IDO inhibitor, 1-methyltryptophan, which was shown to enhance
chemotherapeutic effects in both the murine orthotopic 4T1 and
the autochthonous MMTV-neu breast cancer models (70). Given
these encouraging findings, high throughput screening has been
employed to identify improved compounds for further clinical
trial development (71–73). Although single agent efficacy has
been modest (74), recent reports are showing encouraging clinical
responses when combined with anti-CTLA-4 monoclonal anti-
body therapy while several other combination studies are ongoing
(75–79) (Table 1). These results suggest that immunotherapeu-
tic regimens employing a combinatorial approach including T
cell-targeted immune checkpoint inhibitors and agents capable
of reversing tumor-mediated immune evasion mechanisms have
great promise.
In addition to targeting the IDO immunoregulatory enzyme
itself, pharmacological strategies designed to interfere with the
previously discussed regulatory pathways of IDO have the-
oretical advantages (Figure 3). First, evidence showing that
TGF-β-induced IDO in specific DC subsets is capable of main-
taining immune tolerance via a signaling mechanism that is inde-
pendent of its enzymatic activity suggests that inhibitors targeting
the active site of IDO may have limited clinical benefit (21). Sec-
ond, IDO is likely to only be a component of the tolerogenic DC
program induced by specific tumor-derived mediators, implying
that inhibition of the upstream signals that activate this program
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Table 1 | Active clinical trials investigating the activity of IDO inhibitors in advanced cancer.
Agent Regimen Disease Sponsor ClinicalTrials.gov
Identifier
Phase of
development
Reference
NLG-919 Monotherapy Advanced solid
tumors
New link genetics NCT02048709 I (72)
Indoximod Temozolomide Glioblastoma
multiforme
New link genetics NCT02052648 I/II (75)
Indoximod Docetaxel Breast cancer New link genetics NCT01792050 II (76)
Indoximod Sipuleucel-T Prostate cancer New link genetics NCT01560923 II (77)
Indoximod Ipilimumab Melanoma New link genetics NCT02073123 I/II (78)
INCB024360 Ipilimumab Melanoma Incyte Corp. NCT01604889 I/II (74)
INCB024360 Pembrolizumab Lung cancer and
other solid tumors
Incyte Corp./Merck &
Co.
NCT02178722 I/II clinicalTrials.gov
INCB024360 Anti-DEC-205/NY-ESO-1
vaccine and poly-ICLC
Ovarian, fallopian,
peritoneal cancers
Fred Hutchinson Cancer
Center/CITN/
Celldex Therapeutics
NCT02166905 I/II clinicalTrials.gov
INCB024360 MELITAC multipeptide
vaccine
Melanoma Fred Hutchinson Cancer
Research Center/CITN/
Incyte Corp.
NCT01961115 II clinicalTrials.gov
Ipilimumab, anti-CTLA-4 monoclonal antibody (Bristol-Myers Squibb). Pembrolizumab, anti-PD-1 monoclonal antibody (Merck & Co.). anti-DEC-205-NY-ESO-1, DC-
targeted antibody-peptide fusion vaccine (CDX-1401, Celldex Therapeutics). Poly-ICLC, polyinosinic-polycytidylic acid and poly-L-lysine double-stranded RNA TLR3
agonist (Oncovir, Inc.). MELITAC multipeptide vaccine, emulsion of a mixture of 12 class I MHC-restricted melanoma peptides (University of Virginia), CITN, Cancer
Immunotherapy Network.
FIGURE 3 | Potential pharmacological strategies for suppressing IDO
expression in the tumor microenvironment. (A) TGF-β inhibitors.
GC1008, pan-TGF-β isoform monoclonal antibody (Genzyme), LY2157299,
type I TGF-β receptor serine/threonine kinase small molecule inhibitor (Eli
Lilly), TEW-7197, type I TGF-β receptor serine/threonine kinase small
molecule inhibitor (MedPacto, Inc.). (B) Wnt inhibitors. LGK974, Porcn acyl
transferase small molecule inhibitor (Novartis). (C) Cyclooxygenase-2
(COX2) Inhibitors. Celecoxib (Pfizer, Inc.). pDC, plasmacytoid DC; mDC,
myeloid DC.
are more likely to have greater clinical efficacy. This is exemplified
by TGF-β, which is known to induce other immunosuppressive
pathways involving a variety of cellular targets (54).
Since our studies have indicated that tumor-derived TGF-β
is capable of inducing IDO expression by pDCs and that this
effect is enhanced upon loss of TβRIII in a murine breast can-
cer model, we investigated the ability of an oral type I TGF-β
receptor serine/threonine kinase inhibitor (SM16) to augment
the immunologic response of a Her2/neu vaccine. This work
confirmed that a type I TGF-β receptor serine/threonine kinase
inhibitor could synergistically enhance the CD8+ T cell host
immune response to Her2/neu and effectively suppress the pro-
gression of a Her2/neu-expressing 4T1 breast cancer model (55).
Given these findings as well as the supporting data suggesting that
the loss of TβRIII in murine melanoma models also promotes the
development of an immune suppressive microenvironment, we
investigated the combination of another oral type I TGF-β receptor
kinase inhibitor currently in clinical trial development, LY2157299
monohydrate (80, 81), with anti-CTLA-4 monoclonal antibody
therapy in the Tyr:CreER;BrafCA;Ptenlox/lox transgenic melanoma
mouse model (82). Consistent with our previous findings, this
combinatorial treatment approach also generated a synergistic
anti-tumor response, effectively enhancing the tumor-infiltrating
CD8+ T cell/Treg ratio and suppressing both primary melanoma
development and the establishment of distant metastasis.
As described previously, emerging data suggest that the tumor-
mediated expression of Wnt5a contributes to the generation of an
immunotolerant microenvironment. We, therefore, hypothesized
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that the inhibition of Wnt5a-mediated signaling would also aug-
ment immunotherapy efficacy in melanoma. Several strategies
to inhibit the Wnt-β-catenin pathway have been investigated;
however, one of the more promising approaches is targeting the
membrane-bound O-acyltransferase, Porcn, which catalyzes the
palmitoylation of all vertebrate Wnt ligands, a step necessary for
effective secretion of the Wnt soluble protein family (83, 84). This
work has led to the introduction of LGK974, a small molecule
Porcn acyltransferase inhibitor, into early phase clinical trials (85).
To determine if the inhibition of Wnt secretion by targeting Porcn
would be an effective approach for reversing melanoma-mediated
immune suppression, we genetically silenced Porcn expression by
the B16 murine melanoma model and performed several in vivo
tumor assays. This new B16-PORCNKD cell line was found to
exhibit impaired Wnt secretion, suppressed tumor growth in vivo,
and for this to be associated with both enhanced levels of infil-
trating CD8+ T cells and suppressed levels of PD-1-expressing
tumor-infiltrating lymphocytes. With this data, we then evaluated
the ability of a commercially available pharmacological inhibitor
of Porcn, C59, to reverse B16-mediated immune suppression (86).
Given as monotherapy to mice bearing B16 melanomas, this agent
did not seem to exhibit a significant anti-tumor effect, however,
when combined with anti-CTLA-4 monoclonal antibody ther-
apy, a synergistic enhancement in activated 41BB+ TRP2-specific
CD8+ tumor-infiltrating lymphocytes were observed along with
B16 tumor growth suppression. Together, these data support the
use of combinatorial immunotherapy strategies that involve agents
capable of interfering with tumor immune evasion pathways
including the upregulation of local IDO expression.
CONCLUSION
Studies focused on understanding the interplay between tumor
development and the host immune system are now revealing an
intimate relationship between the processes of tumor invasion and
metastasis and the active induction of immune tolerance. Rather
than developing as a response to immune-mediated selective pres-
sure, we hypothesize that some immune evasion mechanisms are
capable of developing at a very early stage in carcinogenesis and
simultaneously promoting tumor invasion while also interfering
with tumor detection by the host immune system. The pathways
that we have found to meet these criteria are induced by intrin-
sic genetic alterations, resulting in the downregulation of both
the BIN-1 and TβRIII tumor suppressors and the upregulation
of the pro-tumorigenic factors, COX2 and Wnt5a. Interestingly,
this body of work also highlights important differences in cell-
specific IDO expression kinetics. While IFN-γ is a rapid inducer
of IDO expression in many cell types, studies are now demonstrat-
ing that the loss of TβRIII in a TGF-βhi tumor microenvironment
promotes durable IDO expression by pDCs while the upregula-
tion of the Wnt5a oncogene results in durable IDO expression
by mDC populations (Figures 2C,D). We expect for several other
tumor-mediated soluble factors or perhaps exosome-derived fac-
tors to also regulate IDO expression via similar paracrine signaling
mechanisms. Their identification will be important for therapeu-
tic development as well as for the establishment of predictive
biomarkers to determine when these novel therapeutic strategies
would be most effectively employed. Importantly, pre-clinical
experimental investigation, to date, suggests that the use of a phar-
macologic agent to inhibit these tumor-mediated evasion path-
ways which target IDO activity effectively synergize with immune
checkpoint blockade. These data strongly support the physiologic
relevance of these novel immune evasion pathways, which target
IDO activity within the tumor microenvironment.
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